Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher  Cell 

Slides:



Advertisements
Similar presentations
Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.
Advertisements

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll  Cancer Cell 
Cellular and Molecular Mechanisms of Liver Injury
Obesity and Cancer: The Oil that Feeds the Flame
IL-22 Gets to the Stem of Colorectal Cancer
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
Inflammation and Colon Cancer
Targeting Aneuploidy for Cancer Therapy
CD5: A New Partner for IL-6
Adrienne D. Cox, Kenneth P. Olive  Cancer Cell 
Cancer Immunotherapy by Dendritic Cells
A Novel ER Stress-Independent Function of the UPR in Angiogenesis
Cellular and Molecular Mechanisms of Liver Injury
K. Lenhard Rudolph, Daniel Hartmann, Oliver G. Opitz  Gastroenterology 
Volume 26, Issue 5, Pages (November 2014)
ROS Function in Redox Signaling and Oxidative Stress
Chi-Ping Day, Glenn Merlino, Terry Van Dyke  Cell 
Tumor Evolution: A Problem of Histocompatibility
Endoplasmic reticulum stress in liver disease
A Novel ER Stress-Independent Function of the UPR in Angiogenesis
Justin D. Lathia, John M. Heddleston, Monica Venere, Jeremy N. Rich 
Volume 26, Issue 1, Pages 1-2 (July 2014)
Wild-Type p53: Tumors Can't Stand It
Metastasis-Promoting Immunity: When T Cells Turn to the Dark Side
Macrophages and Therapeutic Resistance in Cancer
On the TRAIL to Overcome BRAF-Inhibitor Resistance
The Microenvironmental Landscape of Brain Tumors
Macrophages and Therapeutic Resistance in Cancer
ER stress-induced inflammation: does it aid or impede disease progression?  Abhishek D. Garg, Agnieszka Kaczmarek, Olga Krysko, Peter Vandenabeele, Dmitri.
Inflammation, Autophagy, and Obesity: Common Features in the Pathogenesis of Pancreatitis and Pancreatic Cancer  Ilya Gukovsky, Ning Li, Jelena Todoric,
Metabolic Reprogramming of Immune Cells in Cancer Progression
Understanding the Intersections between Metabolism and Cancer Biology
Volume 36, Issue 1, Pages 2-14 (October 2009)
ER Stress in Dendritic Cells Promotes Cancer
Mechanisms of immune escape in the tumor microenvironment.
Volume 26, Issue 5, Pages (November 2014)
Figure 2 Dominance of the cell-extrinsic effects of autophagy
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Volume 84, Issue 1, Pages (July 2013)
Probing the Diversity of T Cell Dysfunction in Cancer
Turning Tumors into Vaccines: Co-opting the Innate Immune System
Metabolic Instruction of Immunity
The RAF Inhibitor Paradox Revisited
Volume 69, Issue 4, Pages (October 2018)
Volume 140, Issue 6, Pages (March 2010)
Tumor Promotion via Injury- and Death-Induced Inflammation
Lung Cancer Resets the Liver’s Metabolic Clock
Frances Balkwill, Kellie A. Charles, Alberto Mantovani  Cancer Cell 
A New FOXO Pathway Required for Leukemogenesis
Tumor-Associated Macrophages: From Mechanisms to Therapy
Elanor N. Wainwright, Paola Scaffidi  Trends in Cancer 
Jürgen C. Becker, David Schrama  Journal of Investigative Dermatology 
Nat. Rev. Urol. doi: /nrurol
Wenjun Ouyang, Anne O’Garra  Immunity 
Macrophage Diversity Enhances Tumor Progression and Metastasis
Volume 22, Issue 2, Pages (August 2012)
Deciphering and Reversing Tumor Immune Suppression
Inflammation, ROS, and Mutagenesis
IL-7 Knocks the Socs Off Chronic Viral Infection
Why Proteasome Inhibitors Cannot ERADicate Multiple Myeloma
Andy J. Minn, E. John Wherry  Cell 
Polarization of Tumor-Associated Macrophages: A Novel Strategy for Vascular Normalization and Antitumor Immunity  Yuhui Huang, Matija Snuderl, Rakesh.
Releasing the Brakes on Cancer Immunotherapy
Immunity, Inflammation, and Cancer
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Discovery of a Secreted Tumor Suppressor Provides a Promising Therapeutic Strategy for Follicular Lymphoma  Marc R. Mansour, A. Thomas Look  Cancer Cell 
Endoplasmic Reticulum Stress in Malignancy
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Dietmar M.W. Zaiss, William C. Gause, Lisa C. Osborne, David Artis 
Presentation transcript:

Tumorigenic and Immunosuppressive Effects of Endoplasmic Reticulum Stress in Cancer  Juan R. Cubillos-Ruiz, Sarah E. Bettigole, Laurie H. Glimcher  Cell  Volume 168, Issue 4, Pages 692-706 (February 2017) DOI: 10.1016/j.cell.2016.12.004 Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 1 Tumor Microenvironmental Factors and Conditions Perturbing ER Homeostasis Malignant transformation mediated by oncogene activation and loss of tumor suppressor function places intense biosynthetic and bioenergetic demands on available cellular resources, triggering initial ER stress. Cancer cells may eventually adapt to these early challenges, yet as tumors expand, they encounter a host of new environmental stresses, including oxygen and nutrient deprivation, lactic acidosis, and multiple forms of clinical intervention. These stimuli can disrupt ER protein folding by limiting crucial reaction intermediates (i.e., O2 and N-acetylglucosamine) or by directly disrupting chaperone function via ROS-mediated lipid peroxidation and covalent adduct formation. Cell 2017 168, 692-706DOI: (10.1016/j.cell.2016.12.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 2 Consequences of ER Stress in Cancer Cells Sublethal UPR activation and signaling via IRE1α, PERK, and ATF6α sustain multiple cell-intrinsic and cell-extrinsic mechanisms of tumor progression. ER-stress-mediated activation of central signaling hubs, such as HIF1α, STAT3, NRF2, and NFκB, facilitates cell survival under harsh microenvironmental conditions and preserves tumor-initiating cell function. Cytokine-driven angiogenesis delivers much-needed oxygen and nutrients into the tumor bed, though IRE1α-deficient cells can also utilize vessel co-option. Intrinsic cancer cell apoptotic resistance is likely crucial for harnessing ER stress to enhance tumor growth. Cell 2017 168, 692-706DOI: (10.1016/j.cell.2016.12.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 3 Effects of ER Stress in Cancer-Associated Myeloid Cells IRE1α-XBP1 overactivation in tDCs is driven by lipid peroxidation byproducts like 4-HNE. This process disrupts their lipid metabolic homeostasis and cripples antigen presentation to T cells, thereby impeding the development of protective immune responses. Neutrophils and MDSCs use IRE1α-XBP1 and CHOP, respectively, to express factors, such as arginase, that actively suppress T cell function. It is unknown whether IRE1α-XBP1 activation is required for the development of MDSCs in cancer hosts. IL-4 and IL-6 signaling triggers cathepsin expression in macrophages via IRE1α-XBP1 activation to promote cancer cell invasion. It is plausible to speculate that other tumor-associated myeloid cells, besides macrophages, could use the ER stress response to secrete factors that promote cancer cell survival and aggressiveness. Whether macrophages and/or cancer cells also use ER stress response factors to directly inhibit T cell function within tumor masses is unknown. Cell 2017 168, 692-706DOI: (10.1016/j.cell.2016.12.004) Copyright © 2017 Elsevier Inc. Terms and Conditions

Figure 4 Therapeutic Strategies to Control ER Stress Responses in Cancer The IRE1α kinase domain can be inactivated using compounds like KIRA6, leading to allosteric inhibition of the IRE1α RNase domain. Other compounds, such as 4μ8c, MKC-3946, and B-I09, can directly inhibit the IRE1α RNase domain to prevent splicing of the Xbp1 mRNA. Treatment with these IRE1α inhibitory compounds could be effective to reduce tolerance to hypoxia, angiogenesis, drug resistance, and metastatic capacity by cancer cells. These compounds could also be used to reprogram the function of cancer-associated myeloid cells, including macrophages, DCs, and neutrophils. Furthermore, siRNA-loaded nanoparticles could be effective for selectively silencing ERN1 or XBP1 in ovarian-cancer-associated DCs. Novel genome-editing technologies could be used to ablate IRE1α-XBP1 signaling in DC-based therapeutic vaccines for cancer. Recently developed inhibitors of PERK and eIF2α could be exploited to control CHOP overexpression by MDSCs and relieve immunosuppression in the tumor microenvironment. However, CHOP-independent roles of PERK/eIF2α in MDSCs have not been explored. Whether the ATF6α arm of the UPR also operates as a modulator of immune cell function in tumors has not been determined. Cell 2017 168, 692-706DOI: (10.1016/j.cell.2016.12.004) Copyright © 2017 Elsevier Inc. Terms and Conditions